Recombinant human growth factors, particularly granulocyte-macrophage
colony-stimulating factor (GM-CSF), have been only available for a few
years. Since their introduction they have affected the management of
drug-induced neutropenia, the use of dose intensive chemotherapy regim
ens and in the setting of autologous stem cell transplantation. This r
eview addresses the clinical role of GM-CSF, using the data available,
in neutrophil recovery in relation to various health care parameters.